Forgot Password

Please enter your email below.*
To create your new password, please enter your email address below.
We will send an email with instructions to reset your password.
*It must be the same email you used to register for your account
 

Asembia Specialty Pharmacy Summit: Live Virtual Broadcasts




 
PTCE is collaborating with Asembia to bring you 15 Live Virtual Broadcasts throughout the month of May.
Earn up to 22.5 Live CE Credits!

Each CE broadcast is approved for 1.5 contact hours (0.15 CEU) of application-based credit.
The full schedule with session details is listed below by date.
Details
Schedule
Upcoming Sessions
Concluded Sessions
IMPORTANT UPDATE



We're disappointed we won't be seeing you in Las Vegas, but we are working hard to make sure you still receive all the high-quality content you would have at the conference. Throughout May you can attend all of our sessions and participate in live Q&A with the faculty virtually from your home!

Topics include:
  • Pulmonary Arterial Hypertension
  • Hemophilia A
  • Primary Immunodeficiency Disorder
  • Chronic Lymphocytic Leukemia
  • Psoriatic Arthritis
  • Inflammatory Bowel Disease
  • Diabetic Retinopathy and Macular Edema
  • BTK Inhibitors for B-Cell Malignancies
  • Wet Age-Related Macular Degeneration
  • Hereditary Angioedema
  • Myelofibrosis
  • Cystic Fibrosis
  • Myelodysplastic Syndrome
  • Influenza Treatment
  • Chronic Inflammatory Demyelinating Polyneuropathy

Follow us on social media! #DIP2020

Full Schedule of Upcoming CE Broadcasts
Saturday, May 2, 2020
12:00 PM – 1:30 PM ET
Pulmonary Arterial Hypertension: Advancements to Optimize Treatment
Sunday, May 3, 2020
10:00 AM – 11:30 AM ET
Hemophilia A: Navigating the Therapeutic Landscape
Tuesday, May 5, 2020
8:00 PM – 9:30 PM ET
Primary Immunodeficiency Disorder: Considerations in the Use of Intravenous and Subcutaneous Immunoglobulin
Wednesday, May 6, 2020
8:00 PM – 9:30 PM ET
The Dynamic Landscape of CLL and Its Effect on Specialty Pharmacy Practice
Thursday, May 7, 2020
8:00 PM – 9:30 PM ET
A Review of Psoriatic Arthritis Therapies for Specialty Pharmacists and Payers
Saturday, May 9, 2020
10:00 AM – 11:30 AM ET
Inflammatory Bowel Disease: A Panel Discussion on Clinical and Operational Strategies for Biologic Usage
Tuesday, May 12, 2020
8:00 PM – 9:30 PM ET
Diabetic Retinopathy and Macular Edema: Treatment and Management Updates
Wednesday, May 13, 2020
8:00 PM – 9:30 PM ET
BTK Inhibitors for B-Cell Malignancies: Clinical Updates for Specialty Pharmacists
Thursday, May 14, 2020
8:00 PM – 9:30 PM ET
Wet Age-Related Macular Degeneration: Examining Clinical and Economic Data
Sunday, May 17, 2020
10:00 AM – 11:30 AM ET
Hereditary Angioedema: Outlining the Differences Between Current and Emerging Therapies
Monday, May 18, 2020
8:00 PM – 9:30 PM ET
Updates in Myelofibrosis: The Significance of JAK Inhibitors in Therapy
Tuesday, May 19, 2020
8:00 PM – 9:30 PM ET
Comprehensive Cystic Fibrosis Management: A Review for Specialty Pharmacists
Wednesday, May 20, 2020
8:00 PM – 9:30 PM ET
Myelodysplastic Syndrome and Myelodysplastic-associated Anemia: Exploring Clinical Treatment Updates
Thursday, May 21, 2020
8:00 PM – 9:30 PM ET
Influenza Treatment: Exploring the Clinical and Economic Benefits of Antivirals
Wednesday, May 27, 2020
8:00 PM – 9:30 PM ET
Chronic Inflammatory Demyelinating Polyneuropathy: Assessing the Application of Intravenous and Subcutaneous Immunoglobulin, Featuring a Patient Perspective
  Registration links are listed on the next tab.
 
To register for an event, a PharmacyTimes account is required. Please create one or if you already have one, please choose a session below:
 

Chronic Inflammatory Demyelinating Polyneuropathy: Assessing the Application of Intravenous and Subcutaneous Immunoglobulin, Featuring a Patient Perspective

Date: Wednesday, May 27, 2020
Time: 8:00 PM – 9:30 PM ET

Description:
Chronic inflammatory demyelinating polyneuropathy is a rare, debilitating, and degenerative neurologic illness characterized by progressive weakness due to peripheral nerve damage. Inflammation of nerve roots and peripheral nerves results in myelin sheath destruction and subsequent impairment of motor and sensory functioning of extremities. If left untreated, an estimated 30% of patients would eventually become wheelchair dependent. Current treatment options provide symptomatic improvement and include corticosteroids, immunosuppressive agents, intravenous and subcutaneous immunoglobulin, and plasma exchange. This activity will provide an overview of CIDP, including a discussion on the burden of illness on patient quality of life and economic effect due to health care usage, focus on the intricacies of CIDP management, and implications for specialty pharmacy. The presentation will include an interview with a patient describing his journey living with CIDP, navigating treatment, and experiences in interacting with pharmacists.

 

 
To register for an event, a PharmacyTimes account is required. Please create one or if you already have one, please choose a session below:
 

Pulmonary Arterial Hypertension: Advancements to Optimize Treatment

Date: Saturday, May 2, 2020
Time: 12:00 PM – 1:30 PM ET

Description:
Pulmonary arterial hypertension (PAH) is a chronic, progressive illness that carries a poor prognosis. Over the past decade, treatment approaches have evolved and now include oral, inhaled, intravenous, and subcutaneous delivery methods. Patients diagnosed with this illness must navigate many drug-related issues and a coordinated, interdisciplinary approach is crucial to optimize outcomes. Specialty pharmacists are positioned as a liaison between the patient and provider and are critical in facilitating access and providing treatment monitoring and education. This activity will enhance pharmacists’ understanding of the current treatment paradigm, highlight recent CHEST guideline updates, and provide operational strategies to improve care for patients with PAH.

This session has concluded. Registration is no longer available.
 

Hemophilia A: Navigating the Therapeutic Landscape

Date: Sunday, May 3, 2020
Time: 10:00 AM – 11:30 AM ET

Description:
In the management of hemophilia A, prophylactic therapy is considered the standard of care; without prophylactic therapy, patients may experience up to 30 bleeding episodes per year. However, patients can develop inhibitors to treatment, increasing the risk of bleeding. Earlier treatments for hemophilia A presented challenges, such as tolerability issues due to the use of albumin or animal products or required frequent infusions due to a short half-life. In the past decade, the hemophilia A landscape has expanded and improved quality of life for patients with hemophilia. This symposium features a hemophilia expert and specialty infusion pharmacist, and will characterize the burden of hemophilia A, investigate clinical data for current and emerging therapies, and discuss management strategies.

This session has concluded. Registration is no longer available.
 

Primary Immunodeficiency Disorder: Considerations in the Use of Intravenous and Subcutaneous Immunoglobulin

Date: Tuesday, May 5, 2020
Time: 8:00 PM – 9:30 PM ET

Description:
Primary immunodeficiency disorder (PID) comprises more than 100 variations and affects about 250,000 Americans. This illness is difficult to diagnose and is characterized by susceptibility to infection, ranging in severity from chronic sinusitis to life-threatening sepsis. Recurring infections can severely affect the patient’s ability to attend school, work, and engage in social activities, thereby decreasing quality of life. Current management strategies include stem cell transplantation or treatment with immunoglobulin to improve immune function. It is critical for pharmacists to be aware of the available immunoglobulins available for intravenous and subcutaneous infusion and appreciate the similarities and differences among the various products. Specialty pharmacists are critical in guiding treatment selection, confirming dosing, and providing education and monitoring. This activity will provide practice pearls for specialty pharmacists to improve care for those affected by PID.

This session has concluded. Registration is no longer available.
 

The Dynamic Landscape of CLL and Its Effect on Specialty Pharmacy Practice

Date: Wednesday, May 6, 2020
Time: 8:00 PM – 9:30 PM ET

Description:
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults, with more than 20,000 patients diagnosed annually in the United States. New and expanded approvals in the past 12 months are changing  the treatment landscape and ultimately the outcomes of patients with CLL. Evidence for the use of oral monotherapy, oral combination therapies, and oral oncolytics in combination with chemoimmunotherapy is rapidly progressing. Specialty pharmacists are uniquely positioned to manage and counsel patients as well as to advise health care professionals about adverse effects and novel guideline-recommended targeted options. This session will highlight the latest information on therapeutic strategies for patients with CLL as well as the pharmacist’s role in developing patient-centered solutions, including coordination of care across practice settings, adherence and monitoring strategies, and patient self-care management.

This session has concluded. Registration is no longer available.
 

A Review of Psoriatic Arthritis Therapies for Specialty Pharmacists and Payers

Date: Thursday, May 7, 2020
Time: 8:00 PM – 9:30 PM ET

Description:
Psoriatic arthritis is an inflammatory form of arthritis, affecting approximately 30% of patients with psoriasis. Up to 60% of patients with psoriatic arthritis experience progressive, erosive, and deforming joint damage. Early intervention is critical to improving clinical outcomes in psoriatic arthritis. The introduction of biologic agents, usually in combination with oral small molecules, has changed the treatment landscape. Despite advances in therapy, some patients do not respond to oral small molecules or anti-TNF-α. Newer classes of biologics have emerged, targeting interleukin (IL)-17, IL-23/23, and JAK molecules to address this unmet need. This live program features a clinical expert in psoriatic arthritis and a specialty pharmacist to review the pathophysiology and burden of psoriatic arthritis, examine clinical data for current and emerging therapies, investigate the costs associated with psoriatic arthritis, and explore how specialty pharmacists can better help patients with psoriatic arthritis.

This session has concluded. Registration is no longer available.
 

Inflammatory Bowel Disease: A Panel Discussion on Clinical and Operational Strategies for Biologic Usage

Date: Saturday, May 9, 2020
Time: 10:00 AM – 11:30 AM ET

Description:
Inflammatory bowel disease (IBD) is a chronic, incurable illness comprising ulcerative colitis and Crohn disease. Goals of treatment in IBD include achieving and maintaining remission, which is often accomplished by pharmacologic treatment. Recent advancements have the potential to provide patients with new options to better control their symptoms and progression of the disease. The specialty pharmacist is ideally situated to work with patients and their providers to select and monitor safe, effective, and cost-effective therapies that improve quality of life and optimize patient outcomes. This expert panel discussion will highlight strategies for managing IBD as well as review recently approved agents, updated treatment guidelines, recent clinical trial data on biologics and biosimilars, and real-world data on how specialty pharmacists are helping to manage this complex disease.

This session has concluded. Registration is no longer available.
 

Diabetic Retinopathy and Macular Edema: Treatment and Management Updates

Date: Tuesday, May 12, 2020
Time: 8:00 PM – 9:30 PM ET

Description:
Diabetic retinopathy (DR) is a common microvascular complication affecting approximately 86% of patients with type 1 diabetes and 40% of patients with type 2 diabetes. Overall, nearly 25% of patients with diabetes and DR are at risk for progressing to diabetic macular edema (DME), characterized by edema and retinal thickening, and subsequent vision loss. Mitigating treatment options include nonpharmacologic therapies, such as laser photocoagulation; vitrectomy; and pharmacologic options, such as corticosteroids and vascular endothelial growth factor (VEGF) inhibitors. To improve clinical outcomes in patients with DME, pharmacists must consider severity of disease, patient compliance, and cost-effectiveness of agents prior to selection of therapy. This activity will highlight several opportunities for specialty pharmacists to take active roles in counseling patients from the importance of managing their diabetes and other comorbidities contributing to DR and DME to inquiring about patients’ adherence to regularly scheduled eye examinations.

This session has concluded. Registration is no longer available.
 

BTK Inhibitors for B-Cell Malignancies: Clinical Updates for Specialty Pharmacists

Date: Wednesday, May 13, 2020
Time: 8:00 PM – 9:30 PM ET

Description:
B-cell malignancies are a heterogenous group of cancers impacting B lymphocytes and include most non-Hodgkin lymphomas, such as mantle cell lymphoma, as well as chronic lymphocytic leukemia, and Waldenström macroglobulinemia. With multiple oral BTK inhibitors available, it is necessary for specialty pharmacists to be cognizant of expanding approved indications and the latest clinical and safety data for emerging therapies. Considerations as to patient- and disease-specific factors and nuances within this class of medications are essential to ensure individualized and appropriate management of BTK inhibitors. This session will also review the specialty pharmacist’s role on the oncology team in coordinating care and minimizing treatment-related adverse effects to improve adherence and patient outcomes.

This session has concluded. Registration is no longer available.
 

Wet Age-Related Macular Degeneration: Examining Clinical and Economic Data

Date: Thursday, May 14, 2020
Time: 8:00 PM – 9:30 PM ET

Description:
Neovascular or wet age-related macular degeneration (AMD) accounts for 10% to 15% of all cases of AMD. Wet AMD is responsible for about 90% of the loss of severe visual acuity due to accumulation of retinal fluid. Improved imaging technologies and home monitoring systems are transforming the management and diagnosis of patients with wet AMD. However, data indicate that wet AMD may still be underdiagnosed in the United States, and treatment delays can considerably contribute to economic burden for patients, caregivers, and the health care system. Approved and emerging treatment options with anti-vascular endothelial growth factor (VEGF) biologics offer individualized regimens for patients with wet AMD. Specialty pharmacists are well positioned to engage with managed care professionals and payers on the value of best practices to reduce the associated treatment burden of this disease. This session will explore extended dosing schedules of anti-VEGF biologics as well as the pharmacist’s role in promoting strategies for early and aggressive treatment to improve outcomes for patients with wet AMD.

This session has concluded. Registration is no longer available.
 

Hereditary Angioedema: Outlining the Differences Between Current and Emerging Therapies

Date: Sunday, May 17, 2020
Time: 10:00 AM – 11:30 AM ET

Description:
Hereditary angioedema (HAE) is a rare disease characterized by recurring episodes of subcutaneous or submucosal edema, most commonly in the face, gastrointestinal tract, and upper airway. Misdiagnosis of HAE and subsequent emergency department visits, hospital stays, and other indirect costs contribute to its substantial burden. If left untreated, patients with HAE may experience multiple and life-threatening attacks, require more frequent medical interventions, and incur considerable economic costs. Specialty pharmacists must be well informed of the nuances between current recommendations for acute attacks and prophylaxis including C1-INH therapies, kallikrein inhibitors, and bradykinin receptor antagonists to provide patients with individualized treatment plans and proper recommendations for self-administration. This activity will equip pharmacists with the knowledge necessary to educate and counsel patients on appropriate medication use for effective and safe management of HAE attacks.

This session has concluded. Registration is no longer available.
 

Updates in Myelofibrosis: The Significance of JAK Inhibitors in Therapy

Date: Monday, May 18, 2020
Time: 8:00 PM – 9:30 PM ET

Description:
Myelofibrosis is a rare blood cancer with a high rate of mortality within several years of diagnosis. The identification of the certain mutations, including JAK2, CALR, and MPL, has helped to open the treatment landscape to targeted therapies. Janus-associated kinase (JAK) inhibitors are changing the therapeutic landscape from traditional chemotherapy for symptom control and agents to address anemia, and are showing that by stemming disease progression, patients’ lives may be extended. This program will focus on evidence and nuances to available JAK inhibitors and discuss agents in the pipeline for myelofibrosis. Additionally, discussion of cumulative direct and indirect costs associated with myelofibrosis and its acute impact on patients’ quality of life will be addressed.

This session has concluded. Registration is no longer available.
 

Comprehensive Cystic Fibrosis Management: A Review for Specialty Pharmacists

Date: Tuesday, May 19, 2020
Time: 8:00 PM – 9:30 PM ET

Description:
As a genetic life-limiting disease, cystic fibrosis (CF) affects more than 30,000 children and adults in the United States and more than double those individuals worldwide. In the 1950s, the poor survival rate of children diagnosed with CF made it difficult for them to live long enough to enter elementary school, but advancements in therapies have dramatically increased the average lifespan to approximately 37 years. Management of these patients’ disease is complex and includes a combination of therapies with a primary goal of maintaining lung function to as close to normal as possible and providing supplemental therapies. Pharmacists should understand the current care paradigm and the role of CF transmembrane conductance regulator (CFTR) modulators in individuals with specific CF mutations. Specialty pharmacists play an intrinsic role as part of the multidisciplinary team that is able to help monitor and tailor these therapies to provide a personalized approach through patient-specific counseling.

This session has concluded. Registration is no longer available.
 

Myelodysplastic Syndrome and Myelodysplastic-associated Anemia: Exploring Clinical Treatment Updates

Date: Wednesday, May 20, 2020
Time: 8:00 PM – 9:30 PM ET

Description:
Myelodysplastic syndromes (MDS) are a group of relatively rare heterogeneous diseases that affect the blood and bone marrow. Anemia is one of the most common findings in MDS, often requiring blood transfusions to improve quality of life and patient outcomes. Consequences of transfusions include iron overload, necessitating the use of iron chelators. An agent with a new erythroid maturation mechanism has been approved in the past 12 months and additional agents with promising outcomes are in the pipeline. These agents could mitigate the need for transfusions, thereby diminishing the consequences of iron overload in this patient population. This program will examine MDS, the complications of MDS-associated anemia, and innovative treatments for addressing this clinical need. Discussion will include addressing the considerable economic burden of MDS as direct medical resource utilization and treatment and supportive care costs, such as red blood cell transfusions, account for a significant portion of MDS-related costs.

This session has concluded. Registration is no longer available.
 

Influenza Treatment: Exploring the Clinical and Economic Benefits of Antivirals

Date: Thursday, May 21, 2020
Time: 8:00 PM – 9:30 PM ET

Description:
Despite the worldwide concern of influenza every season, the burden remains high, with an estimated 36 million individuals having symptomatic illnesses in the United States in the 2018-2019 season. Antivirals are important in not just decreasing symptoms associated with influenza, but also in reducing complications that may require additional treatment or hospitalization. It is imperative that pharmacists are able to identify individuals who are at high risk of serious influenza-related complications and understand the nuances of the 4 approved antivirals recommended by the CDC this season: baloxavir, oseltamivir, peramivir, and zanamivir. Improving clinical and economic outcomes necessitates an understanding of appropriate diagnostic testing to initiate antiviral therapy, improving timing of antiviral therapy, and assisting with patient access.

This session has concluded. Registration is no longer available.
 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.